Multipla skleroza (Serbo-Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Multipla skleroza" in Serbo-Croatian language version.

refsWebsite

Global rank Serbo-Croatian rank

63nih.gov

4^th place

3^rd place

24doi.org

2^nd place

14web.archive.org

1^st place

6archive.org

6^th place

5^th place

4clinicaltrials.gov

5,225^th place

3,406^th place

3msrc.co.uk

low place

2multipla-skleroza.com

low place

2mult-sclerosis.org

low place

1worldcat.org

5^th place

25^th place

1uff.br

low place

1asm.org

3,555^th place

773^rd place

1msforumonline.net

low place

1neurology.org

9,919^th place

7,561^st place

1healthday.com

low place

1multiplaskleroza.org.rs

low place

1mayoclinic.com

3,634^th place

1,999^th place

1kadbolestugrozava.com

low place

1ajnr.org

low place

1aerzteblatt.de

3,043^rd place

3,578^th place

1europa.eu

68^th place

64^th place

1weizmann.ac.il

4,983^rd place

5,904^th place

1fda.gov

447^th place

642^nd place

1cochrane.org

7,609^th place

2,670^th place

1springerlink.com

2,569^th place

364^th place

1bmj.com

1,226^th place

501^st place

1medscape.com

719^th place

171^st place

1neurologyreviews.com

low place

1yahoo.com

38^th place

116^th place

1nejm.org

2,374^th place

547^th place

1drugs.com

399^th place

1,145^th place

1medicalnewstoday.com

3,011^th place

4,880^th place

1webmd.com

1,169^th place

964^th place

1docguide.com

low place

1reuters.com

49^th place

121^st place

1tysabri.com

low place

1biomedcentral.com

2,747^th place

4,249^th place

1sagepub.com

731^st place

1,123^rd place

1ms-info.net

low place

1stetoskop.info

low place

99^th place

aerzteblatt.de

Rieckmann et al.: Rekombinante Beta-Interferone: Immunmodulatorische Therapie der schubförmigen Multiplen Sklerose. Deutsches Ärzteblatt 93, Ausgabe 46 vom 15. November 1996, Seite A-3022 Volltext

ajnr.org

Wattjes MP, Lutterbey GG, Gieseke J, et al. (1 January 2007). "Double inversion recovery brain imaging at 3T: Diagnostic value in the detection of multiple sclerosis lesions". AJNR Am J Neuroradiol 28 (1): 54–9. PMID 17213424 [2]

archive.org

Ascherio A, Munger KL (April 2007). „Environmental risk factors for multiple sclerosis. Part I: the role of infection”. Ann. Neurol. 61 (4): 288–99. DOI:10.1002/ana.21117. PMID 17444504.
Ascherio A, Munger KL (June 2007). „Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors”. Ann. Neurol. 61 (6): 504–13. DOI:10.1002/ana.21141. PMID 17492755.
SOTELO, J., MARTÍNEZ-PALOMO, A., ORDOÑEZ, G., PINEDA, B (2008). „Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis” ((en)). Ann. Neurol. 63 (3): 303–11. DOI:10.1002/ana.21316. PMID 18306233.
Rudge P, Koetsier JC, Mertin J, Mispelblom B.J.O.,Van Walbeek HK, Jones RC, Harrison J, Robinson K, Mellein B, Poole T (1989). „Randomised double blind controlled trial of cyclosporin in multiple sclerosis”. J Neurol Neurosurg Psychiatry 52: 559-565. DOI:10.1136/jnnp.52.5.559.
Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA (2005). „Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial”. Invest Ophthalmol Vis Sci 46 (10): 3845-9.
Phadke JG (May 1987). „Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland”. J. Neurol. Neurosurg. Psychiatr. 50 (5): 523–31. DOI:10.1136/jnnp.50.5.523. PMC 1031962. PMID 3495637.

asm.org

cmr.asm.org

Kurtzke JF Epidemiologic evidence for multiple sclerosis as an infection, Clin. Microbiol. Rev. 6. 4., strana. 382–427, 1993. PMID 8269393, PMC 358295 [1]

biomedcentral.com

Daumer et al.: Prognosis of the individual course of disease-steps in developing a decision support tool for Multiple Sclerosis. BMC Med Inform Decis Mak. 2007;7:11 PMID 17488517 Volltext

bmj.com

clinicalevidence.bmj.com

Richard Nicholas and Jeremy Chataway. „Corticosteroids versus each other”. ^{[mrtav link]}

clinicaltrials.gov

cochrane.org

www2.cochrane.org

Gray O, McDonnell GV, Forbes RB (2004). „Methotrexate for multiple sclerosis”. Cochrane Reviews. DOI:10.1002/14651858.CD003208.pub2. Arhivirano iz originala na datum 2010-09-12. Pristupljeno 2010-10-03.

docguide.com

Temsirolimus Reduces Rate of Brain Atrophy in Patients With Relapsing-Remitting MS: Presented at ECTRIMS

doi.org

dx.doi.org

Rosati G (April 2001). „The prevalence of multiple sclerosis in the world: an update”. Neurol. Sci. 22 (2): 117–39. DOI:10.1007/s100720170011. ISSN 1590-1874. PMID 11603614.
Compston A, Coles A (October 2008). „Multiple sclerosis”. Lancet 372 (9648): 1502–17. DOI:10.1016/S0140-6736(08)61620-7. PMID 18970977.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). „Vitamin D: an evidence-based review”. J Am Board Fam Med 22 (6): 698–706. DOI:10.3122/jabfm.2009.06.090037. PMID 19897699.
Ascherio A, Munger KL (April 2007). „Environmental risk factors for multiple sclerosis. Part I: the role of infection”. Ann. Neurol. 61 (4): 288–99. DOI:10.1002/ana.21117. PMID 17444504.
Marrie RA (December 2004). „Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol 3 (12): 709–18. DOI:10.1016/S1474-4422(04)00933-0. PMID 15556803.
Ascherio A, Munger KL (June 2007). „Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors”. Ann. Neurol. 61 (6): 504–13. DOI:10.1002/ana.21141. PMID 17492755.
Dyment DA, Ebers GC, Sadovnick AD (February 2004). „Genetics of multiple sclerosis”. Lancet Neurol 3 (92): 104–10. DOI:10.1016/S1474-4422(03)00663-X. PMID 14747002.
Compston A, Coles A (April 2002). „Multiple sclerosis”. Lancet 359 (9313): 1221–31. DOI:10.1016/S0140-6736(02)08220-X. PMID 11955556.
Gilden DH (March 2005). „Infectious causes of multiple sclerosis”. The Lancet Neurology 4 (3): 195–202. DOI:10.1016/S1474-4422(05)01017-3. PMID 15721830.
SOTELO, J., MARTÍNEZ-PALOMO, A., ORDOÑEZ, G., PINEDA, B (2008). „Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis” ((en)). Ann. Neurol. 63 (3): 303–11. DOI:10.1002/ana.21316. PMID 18306233.
LÜNEMANN, JD., KAMRADT, T., MARTIN, R., MÜNZ, C (June 2007). „Epstein-barr virus: environmental trigger of multiple sclerosis?” (en). J. Virol. 81 (13): 6777–84. DOI:10.1128/JVI.00153-07. PMC 1933281. PMID 17459939.
JOHNSTON, JB., SILVA, C., HOLDEN, J., WARREN, KG., CLARK, AW., POWER, C (2001). „Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases” (en). Ann. Neurol. 50 (4): 434–42. DOI:10.1002/ana.1131. PMID 11601494.
Rudge P, Koetsier JC, Mertin J, Mispelblom B.J.O.,Van Walbeek HK, Jones RC, Harrison J, Robinson K, Mellein B, Poole T (1989). „Randomised double blind controlled trial of cyclosporin in multiple sclerosis”. J Neurol Neurosurg Psychiatry 52: 559-565. DOI:10.1136/jnnp.52.5.559.
Gray O, McDonnell GV, Forbes RB (2004). „Methotrexate for multiple sclerosis”. Cochrane Reviews. DOI:10.1002/14651858.CD003208.pub2. Arhivirano iz originala na datum 2010-09-12. Pristupljeno 2010-10-03.
Schmelzeisen R, Frölich JC (2004). „Prevention of postoperative swelling and pain by dexamethasone after operative removal of impacted third molar teeth”. European Journal of Clinical Pharmacology 44 (3): 275–277. DOI:10.1007/BF00271371. ^{[mrtav link]}
Magne D, Mézin F, Palmer G, Guerne PA (2006). „The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha”. Inflamm. Res. 55 (11): 469–75. DOI:10.1007/s00011-006-5196-x. PMID 17122964.
Cohen JA (July 2009). „Emerging therapies for relapsing multiple sclerosis”. Arch. Neurol. 66 (7): 821–8. DOI:10.1001/archneurol.2009.104. PMID 19597083.
Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG (2007). „Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results”. Neurology 69 (8): 785–789. DOI:10.1212/01.wnl.0000267662.41734.1f. PMID 17709711.
Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfield R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P for the FREEDOMS Study Group (2010). „A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis”. New England Journal of Medicine 362 (5): epub ahead of print. DOI:10.1056/NEJMoa0909494. PMID 20089952.
Comi G, Pulizzi A, Rovaris M, et al (June 2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet 371 (9630): 2085–92. DOI:10.1016/S0140-6736(08)60918-6. PMID 18572078.
Polman C, Barkhof F, Sandberg-Wollheim M et al (March 2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology 64 (6): 987–91. DOI:10.1212/01.WNL.0000154520.48391.69. PMID 15781813.
Keegan BM, Weinshenker BG (June 2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet 371 (9630): 2059–60. DOI:10.1016/S0140-6736(08)60894-6. PMID 18572062.
Weinshenker BG (1994). „Natural history of multiple sclerosis”. Ann. Neurol. 36 (Suppl): S6–11. DOI:10.1002/ana.410360704. PMID 8017890.
Phadke JG (May 1987). „Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland”. J. Neurol. Neurosurg. Psychiatr. 50 (5): 523–31. DOI:10.1136/jnnp.50.5.523. PMC 1031962. PMID 3495637.

drugs.com

„Bayhill Therapeutics to Present Phase II Follow-up Data on BHT-3009 for Treatment of Multiple Sclerosis”. Arhivirano iz originala na datum 2011-08-06. Pristupljeno 2010-10-03.

europa.eu

ema.europa.eu

„European public assessment peport (EPAR), Betaferon”. ^{[mrtav link]}

fda.gov

accessdata.fda.gov

„Prescribing information for Copaxone (glatiramer acetate)”.

healthday.com

consumer.healthday.com

Multipla skleroza ne treba sprečiti trudnoću?^{[mrtav link]} Posjećeno; jun 2010.((en))

kadbolestugrozava.com

„Multipla skleroza (MS) i psihološki distres (psihološka patnja i potresenost)”. Arhivirano iz originala na datum 2010-04-05. Pristupljeno 2010-10-03.

mayoclinic.com

„Faktori rizika u MS” (en). Pristupljeno jun 2010.

medicalnewstoday.com

„Adeona Announces Additional $860,000 Grant For Oral Estriol Multiple Sclerosis Clinical Trial”. Arhivirano iz originala na datum 2010-07-22. Pristupljeno 2010-10-03.

medscape.com

Carsten Lukas; Barbara Bellenberg; Horst K. Hahn; Jan Rexilius; Robert Drescher; Kerstin Hellwig; Odo Köster; Sebastian Schimrigk (2009). „Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy”. Ther Adv Neurol Disorders 2 (6): 349-355.. Arhivirano iz originala na datum 2010-12-31. Pristupljeno 2010-10-03.

ms-info.net

„Damaging venous reflux into the skull or spine:Relevance to multiple sclerosis” (en). Pristupljeno maj 2010.

msforumonline.net

CHRISTENSEN, T (2006). „The role of EBV in MS pathogenesis” (en) (PDF). Int MS J 13 (2): 52–7. PMID 16635422. ^{[mrtav link]}

msrc.co.uk

mult-sclerosis.org

„www.mult-sclerosis.org”.
Multiple Sclerosis Treatments Posjećeno:jun 2010. (en)

multipla-skleroza.com

„Multipla skleroza - klinički simptomi”. Arhivirano iz originala na datum 2010-05-22. Pristupljeno 2010-10-03.
Fizikalna terapija u MS Arhivirano 2010-08-25 na Wayback Machine-u Posećeno:jun 2010.

multiplaskleroza.org.rs

Trudnoća i MS Arhivirano 2011-11-25 na Wayback Machine-uPosjećeno;jun 2010.

nejm.org

content.nejm.org

„NEJM - B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis”. Arhivirano iz originala na datum 2009-08-28. Pristupljeno 2010-10-03.

neurology.org

YAO, SY., STRATTON, CW., MITCHELL, WM., SRIRAM, S (2001). „CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens” (en). Neurology 56 (9): 1168–76. PMID 11342681.

neurologyreviews.com

„Use for MS”. Arhivirano iz originala na datum 2009-04-01. Pristupljeno Sept 2007.

nih.gov

ncbi.nlm.nih.gov

Rosati G (April 2001). „The prevalence of multiple sclerosis in the world: an update”. Neurol. Sci. 22 (2): 117–39. DOI:10.1007/s100720170011. ISSN 1590-1874. PMID 11603614.
Pearce: Historical descriptions of multiple sclerosis. Eur Neurol. 2005;54(1):49-53. PMID 16103678 Abstract Posjećeno; maj 2010.
Compston A, Coles A (October 2008). „Multiple sclerosis”. Lancet 372 (9648): 1502–17. DOI:10.1016/S0140-6736(08)61620-7. PMID 18970977.
Kulie T, Groff A, Redmer J, Hounshell J, Schrager S (2009). „Vitamin D: an evidence-based review”. J Am Board Fam Med 22 (6): 698–706. DOI:10.3122/jabfm.2009.06.090037. PMID 19897699.
Ascherio A, Munger KL (April 2007). „Environmental risk factors for multiple sclerosis. Part I: the role of infection”. Ann. Neurol. 61 (4): 288–99. DOI:10.1002/ana.21117. PMID 17444504.
Marrie RA (December 2004). „Environmental risk factors in multiple sclerosis aetiology”. Lancet Neurol 3 (12): 709–18. DOI:10.1016/S1474-4422(04)00933-0. PMID 15556803.
Ascherio A, Munger KL (June 2007). „Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors”. Ann. Neurol. 61 (6): 504–13. DOI:10.1002/ana.21141. PMID 17492755.
Dyment DA, Ebers GC, Sadovnick AD (February 2004). „Genetics of multiple sclerosis”. Lancet Neurol 3 (92): 104–10. DOI:10.1016/S1474-4422(03)00663-X. PMID 14747002.
Compston A, Coles A (April 2002). „Multiple sclerosis”. Lancet 359 (9313): 1221–31. DOI:10.1016/S0140-6736(02)08220-X. PMID 11955556.
Gilden DH (March 2005). „Infectious causes of multiple sclerosis”. The Lancet Neurology 4 (3): 195–202. DOI:10.1016/S1474-4422(05)01017-3. PMID 15721830.
SOTELO, J., MARTÍNEZ-PALOMO, A., ORDOÑEZ, G., PINEDA, B (2008). „Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis” ((en)). Ann. Neurol. 63 (3): 303–11. DOI:10.1002/ana.21316. PMID 18306233.
LÜNEMANN, JD., KAMRADT, T., MARTIN, R., MÜNZ, C (June 2007). „Epstein-barr virus: environmental trigger of multiple sclerosis?” (en). J. Virol. 81 (13): 6777–84. DOI:10.1128/JVI.00153-07. PMC 1933281. PMID 17459939.
FARRELL, RA., ANTONY, D., WALL, GR., CLARK, DA., FISNIKU, L., SWANTON, J, KHALEELI, Z., SCHMIERER, K., MILLER, DH., GIOVANNONI, G (2009). „Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI” (en). Neurology. PMID 19458321.
JOHNSTON, JB., SILVA, C., HOLDEN, J., WARREN, KG., CLARK, AW., POWER, C (2001). „Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases” (en). Ann. Neurol. 50 (4): 434–42. DOI:10.1002/ana.1131. PMID 11601494.
CHRISTENSEN, T (2006). „The role of EBV in MS pathogenesis” (en) (PDF). Int MS J 13 (2): 52–7. PMID 16635422. ^{[mrtav link]}
YAO, SY., STRATTON, CW., MITCHELL, WM., SRIRAM, S (2001). „CSF oligoclonal bands in MS include antibodies against Chlamydophila antigens” (en). Neurology 56 (9): 1168–76. PMID 11342681.
Galetta SL (2001). „The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study)”. J Neuroophthalmol 21 (4): 292-5. PMID 11756862.
La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V. (1994). „Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses”. Eur Neurol 34 (4): 199-203. PMID 7915989.
Diabetic Retinopathy Clinical Research Network (2008). „A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema”. Ophthalmology 115 (9): 1447-9. PMID 18662829.
Hoffmann V, Schimrigk S, Islamova S, Hellwig K, Lukas C, Brune N, Pöhlau D, Przuntek H, Müller T. (2003). „Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients”. J Neurol Sci. 211 (1): 81-4. PMID 12767502.
Magne D, Mézin F, Palmer G, Guerne PA (2006). „The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha”. Inflamm. Res. 55 (11): 469–75. DOI:10.1007/s00011-006-5196-x. PMID 17122964.
Cohen JA (July 2009). „Emerging therapies for relapsing multiple sclerosis”. Arch. Neurol. 66 (7): 821–8. DOI:10.1001/archneurol.2009.104. PMID 19597083.
Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG (2007). „Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results”. Neurology 69 (8): 785–789. DOI:10.1212/01.wnl.0000267662.41734.1f. PMID 17709711.
Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfield R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P for the FREEDOMS Study Group (2010). „A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis”. New England Journal of Medicine 362 (5): epub ahead of print. DOI:10.1056/NEJMoa0909494. PMID 20089952.
Tan IL, Lycklama à Nijeholt GJ, Polman CH et al (April 2000). „Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials”. Mult Scler 6 (2): 99–104. PMID 10773855.
Comi G, Pulizzi A, Rovaris M, et al (June 2008). „Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study”. Lancet 371 (9630): 2085–92. DOI:10.1016/S0140-6736(08)60918-6. PMID 18572078.
Polman C, Barkhof F, Sandberg-Wollheim M et al (March 2005). „Treatment with laquinimod reduces development of active MRI lesions in relapsing MS”. Neurology 64 (6): 987–91. DOI:10.1212/01.WNL.0000154520.48391.69. PMID 15781813.
Keegan BM, Weinshenker BG (June 2008). „Laquinimod, a new oral drug for multiple sclerosis”. Lancet 371 (9630): 2059–60. DOI:10.1016/S0140-6736(08)60894-6. PMID 18572062.
Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; PreCISe study group. (2009). „Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial”. Lancet. 374: 1503-11. PMID 19815268.
Johnson KP (2010). „Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis”. Ther Clin Risk Manag. volume=15 (6): 153-72. PMID 20421914.
Weinshenker BG (1994). „Natural history of multiple sclerosis”. Ann. Neurol. 36 (Suppl): S6–11. DOI:10.1002/ana.410360704. PMID 8017890.
Phadke JG (May 1987). „Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland”. J. Neurol. Neurosurg. Psychiatr. 50 (5): 523–31. DOI:10.1136/jnnp.50.5.523. PMC 1031962. PMID 3495637.
Myhr KM, Riise T, Vedeler C, et al (February 2001). „Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension”. Mult. Scler. 7 (1): 59–65. PMID 11321195. Arhivirano iz originala na datum 2021-02-21. Pristupljeno 2010-10-03.

pubmed.ncbi.nlm.nih.gov

Pearce: Historical descriptions of multiple sclerosis. Eur Neurol. 2005;54(1):49-53. PMID 16103678 Abstract Posjećeno; maj 2010.
Alonso A, Hernán MA, Temporal trends in the incidence of multiple sclerosis: a systematic review, Neurology, 71. 2. pages 129–35, July 2008. PMID 18606967, DOI 10.1212/01
Kurtzke JF Epidemiologic evidence for multiple sclerosis as an infection, Clin. Microbiol. Rev. 6. 4., strana. 382–427, 1993. PMID 8269393, PMC 358295 [1]
Marrie RA (December 2004). "Environmental risk factors in multiple sclerosis aetiology". Lancet Neurol 3 (12): 709–18. doi:10.1016/S1474-4422(04)00933-0. PMID 15556803
Alotaibi et al.: Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004;291(15):1875-9. PMID 15100207
Hulter BM et al:Sexual function in women with advanced multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):83–6. PMID 7608715
Zorzon M et al:Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler. 1999 Dec;5(6):418–27. PMID 10618699
Borello-France D et al:Bladder and sexual function among women with multiple sclerosis. Mult Scler. 2004 Aug;10(4):455–61. PMID 15327046
DasGupta et al:Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol. 2002 Jun;15(3):271 – 8. Review. PMID 12045724
Nelson F, Poonawalla AH, Hou P, Huang F, Wolinsky JS, Narayana PA (October 2007). "Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging". AJNR Am J Neuroradiol 28 (9): 1645–9. doi:10.3174/ajnr.A0645. PMID 17885241
Nelson F, Poonawalla A, Hou P, Wolinsky JS, Narayana PA (November 2008). "3D MPRAGE improves classification of cortical lesions in multiple sclerosis". Mult Scler. 14 (9): 1214–9. doi:10.1177/1352458508094644. PMID 18952832
Wattjes MP, Lutterbey GG, Gieseke J, et al. (1 January 2007). "Double inversion recovery brain imaging at 3T: Diagnostic value in the detection of multiple sclerosis lesions". AJNR Am J Neuroradiol 28 (1): 54–9. PMID 17213424 [2]
Roos KL (March 2003). "Lumbar puncture". Semin Neurol 23 (1): 105–14. doi:10.1055/s-2003-40758. PMID 12870112
Kurtzke JF (1983). "Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)". Neurology 33 (11): 1444–52. PMID 6685237
Thompson et al: Primary progressive multiple sclerosis. Brain. 1997;120:1085–96. Review. PMID 9217691
Confavreux C: Infections and the risk of relapse in multiple sclerosis. Brain. 2002 May;125(Pt 5):933–4. PMID 11960883
Rolak & Fleming: The differential diagnosis of multiple sclerosis. Neurologist. 2007;13(2):57-72. PMID 17351525
Filippini et al.: Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545-52. PMID 12598138
Munari et al.: Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev. 2004;(1):CD004678. PMID 14974077
Casetta et al.: Azathioprine for multiple sclerosis. Cochrane Database Syst Rev. 2007; CD003982. PMID 17943809
Gray et al.:Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev. 2003; CD002936. PMID 14583956
Polman et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. PMID 16510744
Martinelli Boneschi et al.: Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2005; CD002127. PMID 16235298
La Mantia et al.: Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 2007; CD002819. PMID 17253481
Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol. 2006;13:887-95. PMID 16879301
Burton JM, O'Connor PW, Hohol M, Beyene J (2009). "Oral versus intravenous steroids for treatment of relapses in multiple sclerosis". Cochrane Database Syst Rev (3): CD006921. doi:10.1002/14651858.CD006921.pub2. PMID 19588409.
Rietberg et al.: Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005; CD003980. PMID 15674920 (Meta-Analyse)
Kesselring J, Beer S: Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 2005;4(10):643–52 PMID 16168933 (Übersichtsarbeit)
Pittock et al.: Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology. 2004; 62:51–9. PMID 14718697
Daumer et al.: Prognosis of the individual course of disease-steps in developing a decision support tool for Multiple Sclerosis. BMC Med Inform Decis Mak. 2007;7:11 PMID 17488517 Volltext

reuters.com

BioMS multiple sclerosis drug gets FDA fast track

sagepub.com

msj.sagepub.com

Myhr KM, Riise T, Vedeler C, et al (February 2001). „Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension”. Mult. Scler. 7 (1): 59–65. PMID 11321195. Arhivirano iz originala na datum 2021-02-21. Pristupljeno 2010-10-03.

springerlink.com

Schmelzeisen R, Frölich JC (2004). „Prevention of postoperative swelling and pain by dexamethasone after operative removal of impacted third molar teeth”. European Journal of Clinical Pharmacology 44 (3): 275–277. DOI:10.1007/BF00271371. ^{[mrtav link]}

stetoskop.info

Živić S, Ima li nade za oboljele od multiple skleroze ? Stetoskop.info Posećeno; maj 2010.

tysabri.com

What is TYSABRI? Arhivirano 2012-05-03 na Wayback Machine-uPosećeno; jun 2010.(en)

uff.br

medmap.uff.br

MedMap projecto de UFF - Multipla skleroza Arhivirano 2009-01-20 na Wayback Machine-u Posjećeno jun 2010.

web.archive.org

MedMap projecto de UFF - Multipla skleroza Arhivirano 2009-01-20 na Wayback Machine-u Posjećeno jun 2010.
Trudnoća i MS Arhivirano 2011-11-25 na Wayback Machine-uPosjećeno;jun 2010.
„Multipla skleroza - klinički simptomi”. Arhivirano iz originala na datum 2010-05-22. Pristupljeno 2010-10-03.
„Multipla skleroza (MS) i psihološki distres (psihološka patnja i potresenost)”. Arhivirano iz originala na datum 2010-04-05. Pristupljeno 2010-10-03.
„The chemistry of the Copaxone drug”. Arhivirano iz originala na datum 2006-08-13. Pristupljeno 2010-10-03.
Gray O, McDonnell GV, Forbes RB (2004). „Methotrexate for multiple sclerosis”. Cochrane Reviews. DOI:10.1002/14651858.CD003208.pub2. Arhivirano iz originala na datum 2010-09-12. Pristupljeno 2010-10-03.
Carsten Lukas; Barbara Bellenberg; Horst K. Hahn; Jan Rexilius; Robert Drescher; Kerstin Hellwig; Odo Köster; Sebastian Schimrigk (2009). „Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy”. Ther Adv Neurol Disorders 2 (6): 349-355.. Arhivirano iz originala na datum 2010-12-31. Pristupljeno 2010-10-03.
„Use for MS”. Arhivirano iz originala na datum 2009-04-01. Pristupljeno Sept 2007.
„NEJM - B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis”. Arhivirano iz originala na datum 2009-08-28. Pristupljeno 2010-10-03.
„Bayhill Therapeutics to Present Phase II Follow-up Data on BHT-3009 for Treatment of Multiple Sclerosis”. Arhivirano iz originala na datum 2011-08-06. Pristupljeno 2010-10-03.
„Adeona Announces Additional $860,000 Grant For Oral Estriol Multiple Sclerosis Clinical Trial”. Arhivirano iz originala na datum 2010-07-22. Pristupljeno 2010-10-03.
What is TYSABRI? Arhivirano 2012-05-03 na Wayback Machine-uPosećeno; jun 2010.(en)
Fizikalna terapija u MS Arhivirano 2010-08-25 na Wayback Machine-u Posećeno:jun 2010.
Myhr KM, Riise T, Vedeler C, et al (February 2001). „Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension”. Mult. Scler. 7 (1): 59–65. PMID 11321195. Arhivirano iz originala na datum 2021-02-21. Pristupljeno 2010-10-03.

webmd.com

Statin Drugs May Help Treat MS

weizmann.ac.il

„The chemistry of the Copaxone drug”. Arhivirano iz originala na datum 2006-08-13. Pristupljeno 2010-10-03.

worldcat.org

Rosati G (April 2001). „The prevalence of multiple sclerosis in the world: an update”. Neurol. Sci. 22 (2): 117–39. DOI:10.1007/s100720170011. ISSN 1590-1874. PMID 11603614.

yahoo.com

news.yahoo.com

„britainscienceresearch”. ^{[mrtav link]}